Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J. Brose MS, et al. Among authors: vaisman f. Lancet Oncol. 2021 Aug;22(8):1126-1138. doi: 10.1016/S1470-2045(21)00332-6. Epub 2021 Jul 5. Lancet Oncol. 2021. PMID: 34237250 Clinical Trial.
Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?
Ganly I, Nixon IJ, Wang LY, Palmer FL, Migliacci JC, Aniss A, Sywak M, Eskander AE, Freeman JL, Campbell MJ, Shen WT, Vaisman F, Momesso D, Corbo R, Vaisman M, Shaha A, Tuttle RM, Shah JP, Patel SG. Ganly I, et al. Among authors: vaisman m, vaisman f. Thyroid. 2015 Oct;25(10):1106-14. doi: 10.1089/thy.2015.0104. Epub 2015 Aug 12. Thyroid. 2015. PMID: 26148759 Free PMC article.
Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.
Reiners C, Schneider R, Platonova T, Fridman M, Malzahn U, Mäder U, Vrachimis A, Bogdanova T, Krajewska J, Elisei R, Vaisman F, Mihailovic J, Costa G, Drozd V. Reiners C, et al. Among authors: vaisman f. Front Endocrinol (Lausanne). 2020 Jul 10;11:381. doi: 10.3389/fendo.2020.00381. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32754115 Free PMC article. Review.
Choosing Wisely for Thyroid Conditions: Recommendations of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.
Dora JM, Biscolla RPM, Caldas G, Cerutti J, Graf H, Hoff AO, Mazeto GMFS, Magalhães PKR, Mesa CO Junior, Scheffel RS, de Fatima Dos Santos Teixeira P, Vaisman F, Villagelin D, Maia AL; Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. Dora JM, et al. Among authors: vaisman f. Arch Endocrinol Metab. 2021 Nov 1;65(2):248-252. doi: 10.20945/2359-3997000000323. Epub 2021 Feb 15. Arch Endocrinol Metab. 2021. PMID: 33587833 Free PMC article.
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).
Ho AL, Dedecjus M, Wirth LJ, Tuttle RM, Inabnet WB 3rd, Tennvall J, Vaisman F, Bastholt L, Gianoukakis AG, Rodien P, Paschke R, Elisei R, Viola D, So K, Carroll D, Hovey T, Thakre B, Fagin JA; ASTRA investigator group. Ho AL, et al. Among authors: vaisman f. J Clin Oncol. 2022 Jun 10;40(17):1870-1878. doi: 10.1200/JCO.21.00714. Epub 2022 Feb 22. J Clin Oncol. 2022. PMID: 35192411 Free PMC article. Clinical Trial.
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Brose MS, Robinson BG, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Sen S, Oliver JW, Banerjee K, Keam B, Capdevila J. Brose MS, et al. Among authors: vaisman f. Cancer. 2022 Dec 15;128(24):4203-4212. doi: 10.1002/cncr.34493. Epub 2022 Oct 19. Cancer. 2022. PMID: 36259380 Free PMC article. Clinical Trial.
65 results